


CLAIMS:

1. A compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof:

5



wherein

- 10 Q is $(CH_2)_m[CH(R^1)]_n(CH_2)_p$ where n is 0 or 1, and m and p are independently 0, 1 or 2;
 R¹ is hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl or C₃₋₆ alkynyl;
- 15 R² is hydrogen, halogen, C₁₋₆ alkyl optionally substituted by hydroxy or C₁₋₆ alkoxy, or phenyl
 optionally substituted by one or more substituents selected from halogen, C₁₋₆ alkyl, CF₃, OCF₃, OR⁶, CN and methylenedioxo;
- 20 R³, R⁴ and R⁵ are independently hydrogen, halogen, C₁₋₆ alkyl optionally substituted by hydroxy or C₁₋₆
 alkoxy, CF₃, OR⁶, COR⁷, NHCOR⁸, NHCONHR⁸, NHSO₂R⁸, CONHR⁹, CN, SO₂R⁸ or NR¹⁰R¹¹;
 R⁶ is hydrogen, C₂₋₆ alkenyl, C₃₋₆ alkynyl, C₁₋₆ alkyl optionally substituted by hydroxy or C₁₋₆
 alkoxy, aryl or heteroaryl wherein aryl or heteroaryl is optionally substituted by one or more substituents
 selected from halogen, CF₃, OCF₃, CN, C₁₋₆ alkyl, C₁₋₆ alkoxy and methylenedioxo;
- 25 R⁷ is C₁₋₆ alkyl, OR⁶ or phenyl optionally substituted by one or more substituents selected from
 halogen, CF₃, OCF₃, CN, C₁₋₆ alkyl, C₁₋₆ alkoxy and NHCOR⁸;
- 30 R⁸ is C₁₋₆ alkyl, C₂₋₆ alkenyl or C₁₋₆ alkoxy any of which may be optionally substituted by aryl or
 heteroaryl, wherein the aryl or heteroaryl is optionally substituted by one or more substituents selected
 from halogen, CF₃, OCF₃, OR⁶, CN, C₁₋₆ alkyl, methylenedioxo and NR¹⁰R¹¹; C₃₋₆ cycloalkyl wherein the
 ring may contain up to two heteroatoms selected from NR¹², S and O; or aryl or heteroaryl wherein the
 aryl or heteroaryl is optionally substituted by one or more substituents selected from halogen, CF₃, OCF₃,
 OR⁶, CN, C₁₋₆ alkyl, methylenedioxo and NR¹⁰R¹¹;
- 35 R⁹ is C₁₋₆ alkyl, C₁₋₆ alkylphenyl or phenyl, wherein alkyl may be interrupted by oxygen and
 wherein phenyl is optionally substituted by one or more substituents selected from halogen, C₁₋₆ alkyl,
 CF₃, OCF₃, CN, C₁₋₆ alkoxy and methylenedioxo;
- 40 R¹⁰ and R¹¹ are independently hydrogen or C₁₋₆ alkyl, or together with the nitrogen to which they
 are attached form a 5- to 6-membered heterocyclic group which optionally contains an additional
 heteroatom selected from NR¹², O and S; and
- 45 R¹² is hydrogen or C₁₋₆ alkyl;
- 50 provided that the compound is not:
 i) 2-[4-[5-(2,4-dichlorophenyl)furan-2-yl]-1,3-thiazol-2-yl]acetic acid.
2. A compound according to claim 1 wherein Q is CH₂.

3. A compound according to claim 1 or 2 wherein R² is hydrogen or halogen.
4. A compound according to any one of the preceding claims wherein R³, R⁴ and R⁵ are independently, hydrogen, halogen, C₁₋₆ alkyl optionally substituted by hydroxyl or C₁₋₆ alkoxy, CF₃, OR⁶, NHCOR⁸ or CONHR⁹, wherein at least one of R³, R⁴ and R⁵ is other than hydrogen.
5. A compound according to any one of the preceding claims wherein one of R³ and R⁴ is NHCOR⁸ and the other is hydrogen or halogen and R⁵ is hydrogen.
10 6. A compound according to any one of the preceding claims wherein R⁸ is C₁₋₆ alkyl, C₂₋₆ alkenyl or C₁₋₆ alkoxy any of which may be optionally substituted by phenyl wherein the phenyl is optionally substituted by one or more substituents selected from halogen, CF₃, OCF₃, OR⁶, CN, C₁₋₆ alkyl, methylenedioxo and NR¹⁰R¹¹; C₃₋₆ cycloalkyl wherein the ring may contain up to two heteroatoms
15 selected from NR¹², S and O; phenyl optionally substituted by one or more substituents selected from halogen, C₁₋₆ alkyl, CF₃, OCF₃, OR⁶, CN and methylenedioxo; or a 5- to 10-membered mono- or bicyclic heteroaryl group containing up to three heteroatoms selected from O, N and S which heteroaryl group may be substituted by C₁₋₆ alkyl, C₁₋₆ alkoxy or halogen.
20 7. A compound according to claim 6 wherein R⁸ is C₁₋₆ alkyl or C₂₋₆ alkenyl either of which may be optionally substituted by phenyl wherein the phenyl is optionally substituted by one or more substituents selected from halogen, CF₃, OCF₃, OR⁶, CN, C₁₋₆ alkyl, methylenedioxo and NR¹⁰R¹¹; phenyl optionally substituted by one or more substituents selected from halogen, C₁₋₆ alkyl, CF₃, OCF₃, OR⁶, CN and methylenedioxo; or a 5- to 10-membered mono- or bicyclic heteroaryl group containing up to three heteroatoms selected from O, N and S which heteroaryl group may be substituted by C₁₋₆ alkyl, C₁₋₆ alkoxy or halogen.
25 8. A compound of formula (I) as described in any one of Examples 1 to 24 or a pharmaceutically acceptable salt or prodrug thereof.
30 9. A compound selected from:
2-[4-[5-[2-Chloro-4-[(2,4-dichlorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,
35 2-[4-[5-[2-Chloro-4-[3-(4-bromo)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,
2-[4-[5-[2-Chloro-4-[3-(2,4-dichloro)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,
40 2-[4-[5-[2-Chloro-4-[3-(3,5-difluoromethyl)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,
2-[4-[5-[2-Chloro-4-(3-phenylacryloylamino)phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(4-trifluoromethoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(benzothiophene-2-carbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

5 2-[4-[5-[2-Chloro-4-[(6-chloro-4H-chromene-3-carbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3,4-dichlorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

10 2-[4-[5-[2-Chloro-4-[(3-methoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid, and


2-[4-[5-[2-Chloro-4-[(4-trifluoromethoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

and pharmaceutically acceptable salts and prodrugs thereof.


15 10. A compound according to any one of claims 1 to 9, without proviso i), for use in medicine.

11. A process for the preparation of a compound according to any one of claims 1 to 9 which comprises:

reacting a compound of formula (II):




wherein R², R³, R⁴ and R⁵ are as defined in claim 1, with a compound of formula (III):



25 wherein Q is as defined in claim 1 and R¹ is H, C₁₋₆ alkyl or a suitable protecting group; followed, where required, by deprotection of the group OR¹ to give the corresponding carboxylic acid.


30 12. A process for the preparation of a compound according to any one of claims 1 to 9 wherein one or more of R³, R⁴ and R⁵ is NHCOR⁸ which comprises:

reacting a compound of formula (VIII):



wherein one or more of R³, R⁴ and R⁵ is NH₂, R² and Q are as defined in claim 1 and R^A is as defined in claim 11, with a compound of formula (IX):

5



wherein R⁸ is as defined in claim 1, in an amide bond formation reaction.

10 13. A pharmaceutical formulation comprising a compound according to any one of claims 1 to 9, without proviso i), together with a pharmaceutically acceptable carrier or excipient.

14. The use of a compound according to any one of claims 1 to 9, without proviso i), in the manufacture of a medicament for the inhibition of heparanase.

15

15. The use of a compound according to any one of claims 1 to 9, without proviso i), in the manufacture of a medicament for the treatment of cancer.


16. The use as claimed in claim 15 wherein the cancer is:

- 20 (a) a metastatic tumour cell type, such as, melanoma, lymphoma, leukaemia, fibrosarcoma, rhabdomyosarcoma, and mastocytoma; or
 (b) a carcinoma, such as, colorectal cancer, prostate cancer, small cell lung cancer and non-small cell lung cancer, breast cancer, pancreatic cancer, bladder cancer, renal cancer, gastric cancer and ovarian cancer.

25


17. The use of a compound according to any one of claims 1 to 9, without proviso i), in the manufacture of a medicament for the treatment of a disease selected from angiogenesis or an angiogenesis dependent disease, an inflammatory disease, an autoimmune disease and a cardiovascular disease.

30 18. A compound of formula (II):



wherein, R², R³, R⁴ and R⁵ are as defined in claim 1.

19. A compound of formula (X):



(X)

5 wherein Q and R² are as defined in claim 1, R^A is as defined in claim 11, at least one of R³, R⁴ and R⁵ is NO₂ and the remainder are as defined in claim 1.